City Holding Co. boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 13.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,725 shares of the company’s stock after buying an additional 2,741 shares during the period. City Holding Co.’s holdings in Merck & Co., Inc. were worth $2,581,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $39,000. Abich Financial Wealth Management LLC lifted its position in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. Quarry LP bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at $42,000. Roble Belko & Company Inc grew its position in shares of Merck & Co., Inc. by 35.3% in the 1st quarter. Roble Belko & Company Inc now owns 326 shares of the company’s stock worth $43,000 after buying an additional 85 shares during the period. Finally, Strategic Financial Concepts LLC grew its position in shares of Merck & Co., Inc. by 1,475.6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after buying an additional 32,832 shares during the period. 76.07% of the stock is owned by institutional investors.
Merck & Co., Inc. Price Performance
MRK opened at $108.50 on Wednesday. The company’s 50-day simple moving average is $114.98 and its two-hundred day simple moving average is $123.56. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. The stock has a market capitalization of $274.81 billion, a P/E ratio of 120.56, a P/E/G ratio of 1.60 and a beta of 0.39. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63.
Merck & Co., Inc. Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 2.84%. The ex-dividend date was Monday, September 16th. Merck & Co., Inc.’s payout ratio is currently 342.22%.
Wall Street Analysts Forecast Growth
MRK has been the subject of a number of recent research reports. UBS Group lowered their price target on shares of Merck & Co., Inc. from $148.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Bank of America lowered their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Evercore ISI raised Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. Morgan Stanley raised their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Buy” and an average price target of $134.42.
Check Out Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Investing in Travel Stocks Benefits
- 3 Powerful ETFs for Income Seekers Looking to Maximize Gains
- 3 Small Caps With Big Return Potential
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is the Nikkei 225 index?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.